Total Payments
$181,836
2024 Payments
$28,881
Companies
14
Transactions
170
Medicare Patients
661
Medicare Billing
$94,662
Payment Breakdown by Category
Other$92,695 (51.0%)
Consulting$51,607 (28.4%)
Travel$33,048 (18.2%)
Food & Beverage$2,885 (1.6%)
Research$1,600 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $51,607 | 12 | 28.4% |
| Honoraria | $50,575 | 23 | 27.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $42,120 | 11 | 23.2% |
| Travel and Lodging | $33,048 | 74 | 18.2% |
| Food and Beverage | $2,885 | 47 | 1.6% |
| Unspecified | $1,600 | 3 | 0.9% |
Payments by Type
General
$180,236
167 transactions
Research
$1,600
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GRT US Holding, Inc. | $50,546 | 62 | $0 (2022) |
| Averitas Pharma Inc. | $40,299 | 50 | $0 (2024) |
| Scilex Pharmaceuticals Inc. | $23,277 | 12 | $0 (2019) |
| Emergent BioSolutions Inc. | $21,457 | 11 | $0 (2022) |
| Lilly USA, LLC | $12,650 | 3 | $0 (2020) |
| Eli Lilly and Company | $8,834 | 9 | $0 (2019) |
| PFIZER INC. | $6,305 | 7 | $0 (2020) |
| Valeant Pharmaceuticals North America LLC | $4,591 | 10 | $0 (2017) |
| Collegium Pharmaceutical, Inc. | $4,500 | 1 | $0 (2024) |
| Vertex Pharmaceuticals Incorporated | $3,990 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $28,881 | 35 | Averitas Pharma Inc. ($24,381) |
| 2023 | $15,919 | 16 | Averitas Pharma Inc. ($15,919) |
| 2022 | $56,546 | 63 | GRT US Holding, Inc. ($50,546) |
| 2021 | $11,217 | 7 | Emergent BioSolutions Inc. ($7,057) |
| 2020 | $24,150 | 12 | Lilly USA, LLC ($12,650) |
| 2019 | $29,831 | 20 | Scilex Pharmaceuticals Inc. ($12,700) |
| 2018 | $10,700 | 7 | Scilex Pharmaceuticals Inc. ($10,576) |
| 2017 | $4,591 | 10 | Valeant Pharmaceuticals North America LLC ($4,591) |
All Payment Transactions
170 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: PAIN MANAGEMENT | ||||||
| 10/01/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Honoraria | Cash or cash equivalent | $250.00 | General |
| Category: PAIN MANAGEMENT | ||||||
| 07/24/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: PAIN MANAGEMENT | ||||||
| 07/19/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Honoraria | Cash or cash equivalent | $3,300.00 | General |
| Category: PAIN MANAGEMENT | ||||||
| 07/19/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,310.00 | General |
| Category: PAIN MANAGEMENT | ||||||
| 07/19/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Travel and Lodging | Cash or cash equivalent | $37.00 | General |
| Category: PAIN MANAGEMENT | ||||||
| 07/19/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Travel and Lodging | Cash or cash equivalent | $15.01 | General |
| Category: PAIN MANAGEMENT | ||||||
| 06/25/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Travel and Lodging | In-kind items and services | $316.20 | General |
| Category: PAIN MANAGEMENT | ||||||
| 06/25/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Travel and Lodging | In-kind items and services | $292.67 | General |
| Category: PAIN MANAGEMENT | ||||||
| 06/25/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $159.00 | General |
| Category: PAIN MANAGEMENT | ||||||
| 06/25/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Travel and Lodging | In-kind items and services | $145.00 | General |
| Category: PAIN MANAGEMENT | ||||||
| 04/02/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Honoraria | Cash or cash equivalent | $3,300.00 | General |
| Category: PAIN MANAGEMENT | ||||||
| 04/02/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,310.00 | General |
| Category: PAIN MANAGEMENT | ||||||
| 04/02/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Travel and Lodging | Cash or cash equivalent | $151.88 | General |
| Category: PAIN MANAGEMENT | ||||||
| 04/02/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Travel and Lodging | Cash or cash equivalent | $58.66 | General |
| Category: PAIN MANAGEMENT | ||||||
| 04/02/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | Cash or cash equivalent | $21.50 | General |
| Category: PAIN MANAGEMENT | ||||||
| 04/02/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | Cash or cash equivalent | $13.00 | General |
| Category: PAIN MANAGEMENT | ||||||
| 03/18/2024 | Collegium Pharmaceutical, Inc. | Xtampza (Drug), Belbuca | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,500.00 | General |
| Category: Opioid Analgesic | ||||||
| 03/13/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Travel and Lodging | In-kind items and services | $243.10 | General |
| Category: PAIN MANAGEMENT | ||||||
| 03/13/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Travel and Lodging | In-kind items and services | $225.31 | General |
| Category: PAIN MANAGEMENT | ||||||
| 03/13/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Travel and Lodging | In-kind items and services | $213.10 | General |
| Category: PAIN MANAGEMENT | ||||||
| 03/13/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $50.87 | General |
| Category: PAIN MANAGEMENT | ||||||
| 03/12/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Honoraria | Cash or cash equivalent | $1,200.00 | General |
| Category: PAIN MANAGEMENT | ||||||
| 03/08/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $166.00 | General |
| Category: PAIN MANAGEMENT | ||||||
| 02/14/2024 | Averitas Pharma Inc. | QUTENZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $4,290.00 | General |
| Category: PAIN MANAGEMENT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TANEZUMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,600 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 177 | 284 | $77,766 | $23,697 |
| 2022 | 4 | 161 | 263 | $67,902 | $24,483 |
| 2021 | 6 | 155 | 281 | $72,587 | $24,136 |
| 2020 | 6 | 168 | 282 | $71,683 | $22,346 |
Total Patients
661
Total Services
1,110
Medicare Billing
$94,662
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 61 | 142 | $35,642 | $10,845 | 30.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 42 | 58 | $20,416 | $6,667 | 32.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 23 | 23 | $10,833 | $3,183 | 29.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 12 | $3,012 | $1,036 | 34.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 13 | 20 | $3,880 | $960.49 | 24.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2023 | 11 | 12 | $2,436 | $556.80 | 22.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 15 | 17 | $1,547 | $448.14 | 29.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 47 | 87 | $21,837 | $6,711 | 30.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 31 | 56 | $14,056 | $6,051 | 43.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 33 | 41 | $14,432 | $5,227 | 36.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 20 | 29 | $10,208 | $4,508 | 44.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 16 | 29 | $5,626 | $1,411 | 25.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 14 | 21 | $1,743 | $576.44 | 33.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 51 | 106 | $26,606 | $8,028 | 30.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 29 | 72 | $18,072 | $7,605 | 42.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 17 | 23 | $8,096 | $2,673 | 33.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 18 | 18 | $8,478 | $2,475 | 29.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 13 | 29 | $5,626 | $1,711 | 30.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 11 | 15 | $4,485 | $1,137 | 25.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 16 | 18 | $1,224 | $506.86 | 41.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 54 | 120 | $28,680 | $7,836 | 27.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 29 | 64 | $15,296 | $5,924 | 38.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 22 | 27 | $9,045 | $2,543 | 28.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 16 | 16 | $7,184 | $2,218 | 30.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 18 | 23 | $5,256 | $1,537 | 29.2% |
About Dr. Steven Stanos, DO
Dr. Steven Stanos, DO is a Physical Medicine & Rehabilitation healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053329615.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Stanos, DO has received a total of $181,836 in payments from pharmaceutical and medical device companies, with $28,881 received in 2024. These payments were reported across 170 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($51,607).
As a Medicare-enrolled provider, Stanos has provided services to 661 Medicare beneficiaries, totaling 1,110 services with total Medicare billing of $94,662. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Physical Medicine & Rehabilitation
- Other Specialties Interventional Pain Medicine, Pain Medicine
- Location Seattle, WA
- Active Since 08/03/2006
- Last Updated 03/19/2021
- Taxonomy Code 208100000X
- Entity Type Individual
- NPI Number 1053329615
Products in Payments
- Qutenza (Drug) $50,546
- QUTENZA (Drug) $34,731
- ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH (Drug) $23,277
- Narcan (Drug) $15,457
- RELISTOR (Drug) $4,591
- Xtampza (Drug) $4,500
- NO PRODUCT DISCUSSED (Drug) $3,592
- BELBUCA (Drug) $1,500
- SYNCHROMED (Device) $123.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Physical Medicine & Rehabilitation Doctors in Seattle
Martin Childers, Do, Phd, DO, PHD
Physical Medicine & Rehabilitation — Payments: $166,707
Physical Medicine & Rehabilitation $166,707
Dr. Nassim Rad, M.d, M.D
Physical Medicine & Rehabilitation — Payments: $157,428
Physical Medicine & Rehabilitation $157,428
Angeli Mayadev, Md, MD
Physical Medicine & Rehabilitation — Payments: $53,597
Physical Medicine & Rehabilitation $53,597
Glen David, Md, MD
Physical Medicine & Rehabilitation — Payments: $14,366
Physical Medicine & Rehabilitation $14,366
Gavin Nixon, Do, DO
Physical Medicine & Rehabilitation — Payments: $7,237
Physical Medicine & Rehabilitation $7,237
Alfred Gellhorn, Md, MD
Physical Medicine & Rehabilitation — Payments: $5,362
Physical Medicine & Rehabilitation $5,362